



05-10-00

GATT-1637 #

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Anticipated Classification Prior Application: Attorney's  
 of this Application: Exam'r: Mary M. Schmidt Docket No.: Enz-53(C)(FWC)  
 Class \_\_\_\_\_ Subclass \_\_\_\_\_ Group Art Unit: Not Yet Known  
 Prior Group Art Unit: 1635

**FILED BY EXPRESS MAIL**

Hon. Commissioner of Patents and Trademarks  
 Washington, D.C. 20231  
**BOX FWC (if under §1.62)**

Sir:

RECEIVED 5/16/00

MAY 15 2000

TECH CENTER 1600/2800

This is a request for filing a X CONTINUATION        DIVISIONAL  
 CONTINUATION-IN-PART application under        37 CFR §1.60 X 37 CFR §1.62,  
 of pending prior application Serial No. 08/978,632 filed on November 25, 1997 of  
Elazar Rabbani et al.

Inventor(s)

for: **NOVEL PROPERTY EFFECTING AND/OR PROPERTY  
 EXHIBITING COMPOSITIONS FOR THERAPEUTIC AND  
 DIAGNOSTIC USES**

Title of Invention

1. \_\_\_\_\_ Enclosed is a copy of the prior application, as originally filed and an affidavit or declaration verifying it as a true copy.
2. \_\_\_\_\_ A copy of the verified statement under 37 CFR §1.9 and §1.27 establishing small entity status in the prior application is enclosed. Small entity status is still applicable.
3. X The filing fee is calculated as follows:

**CLAIMS AS FILED, LESS ANY CLAIMS CANCELLED BY AMENDMENT**

		RATE				FEE	
	Number Filed		Number Extra	Small Entity	Other Entity	Small Entity	Other Entity
Total Claims	25	=	5	x	\$ 9	\$ 18	= \$ 45
Independent Claims	2	=	0	x	\$ 39	\$ 78	= \$ 0
Multiple Dependent Claims Presented:	Yes	No			\$130	\$260	\$ —
If the difference in Col. 1 is less than zero, enter "0" in Col.2						BASIC FEE	\$690
						\$345	
						TOTAL FEE	\$ 0
						\$390	

**EXPRESS MAIL CERTIFICATE**"Express Mail" Label No. EL491424189USDeposit Date May 8, 2000

I hereby certify that this paper and the attachments herein are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Commissioner of Patents and Trademarks, Washington DC 20231.

Ronald C. Fedus  
 Reg. No. 32,567

May 8 2000

Date

05/12/2000 WAN11 00000085 051135 08978632  
 05/08/2000 WAN11 00000085 051135 08978632  
 01 FC:131 690.00 CH

**Attorney's Docket No. Enz-53(C)(FWC)**

Elazar Rabbani et al.  
Serial No.: Not Yet Assigned  
Filed: Herewith  
Page: 2 (Request for a Continuation Application Under 37 C.F.R. §1.62 -  
May 8, 2000)

RECEIVED

MAY 5 2000

TECH CENTER 1600/2000

4.  The Commissioner is hereby authorized to charge payment of the filing fee as well as the following fees associated with this application or to credit any overpayment to Deposit Account No. 05-1135. A duplicate copy of this sheet is enclosed.

Any additional filing fees required under 37 CFR §1.16.

Any patent application processing fees under 37 CFR §1.17.

5.  The Commissioner is hereby authorized to charge payment of the following fees during the pendency of this application or credit any overpayment to Deposit Account No. 05-1135. A duplicate copy of this sheet is enclosed.

Any patent application processing fees under 37 CFR §1.17.

The issue fee set in 37 CFR §1.18 at or before mailing of the

Notice of Allowance, pursuant to 37 CFR §1.311(b).

Any filing fees under 37 CFR §1.16 for presentation of extra claims.

6. \_\_\_\_\_ A check in the amount of \$ \_\_\_\_\_ is enclosed.

7. \_\_\_\_\_ Cancel claims \_\_\_\_\_

8.  Amend the specification by inserting before the first line of the sentence: This is a  continuation,  divisional,  continuation-in-part, of application Serial No. 08/978,632, filed on November 25, 1997

E1  
9. \_\_\_\_\_ Transfer the drawings from the prior application.

10. \_\_\_\_\_ Informal \_\_\_\_\_ Formal \_\_\_\_\_ drawings are enclosed.

11. \_\_\_\_\_ Abandon said prior application as of the filing date accorded this application. A duplicate copy of this sheet is enclosed for filing in the prior application file.

12. \_\_\_\_\_ Priority of application Serial No. \_\_\_\_\_ filed on \_\_\_\_\_ is claimed under 35 U.S.C. §119. \_\_\_\_\_ The certified copy of the priority application has been filed in prior application Serial No. \_\_\_\_\_, filed \_\_\_\_\_

13. \_\_\_\_\_ The prior application is assigned of record to Enzo Therapeutics, Inc., c/o Enzo Biochem, Inc., 527 Madison Avenue, New York, New York 10022. [A copy of the originally submitted Assignment and the Notice of Recordation are enclosed herewith.]

14. \_\_\_\_\_ A preliminary amendment is enclosed.

Elazar Rabbani et al.  
Serial No.: Not Yet Assigned  
Filed: Herewith  
Page: 3 (Request for a Continuation Application Under 37 C.F.R. §1.62 -  
May 8, 2000)

15.  The power of attorney in the prior application is to:  
Ronald C. Fedus, Reg. No. 32,567.

(a)  The power appears in the original papers in the prior application.

(b)  Since the power does not appear in the original papers, a copy of the power in the prior application is enclosed.

(c)  A copy of a new substitute power of attorney is enclosed.

(d)  Address all future communications to: (May only be completed by applicant, or attorney or agent of record.)


Ronald C. Fedus, Esq.  
Enzo Therapeutics, Inc.  
c/o Enzo Biochem, Inc.  
527 Madison Avenue (9th Floor)  
New York, New York 10022

16.  I hereby verify that the attached papers are a true copy of prior application Serial No. \_\_\_\_\_.

The undersigned declares further that all statements made herein of his own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

May 8, 2000

Date



Ronald C. Fedus

Registration No. 32, 567

Attorney for Applicants

Inventor(s)

Assignee of Complete Interest

Attorney or Agent of Record

Filed under 37 CFR §1.34(a)

Address of Signator:  
Enzo Therapeutics, Inc.  
c/o Enzo Biochem, Inc.  
527 Madison Avenue (9th Floor)  
New York, New York 10022

lctword\wsprosecution\enz53\FWC.050800